Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1555447 | 0.89 | RAB9A (0.39) | RAB9AKDM4EMAPTCETPCYP2D6 | |
| SCHEMBL1555550 | 0.87 | RAB9A (0.38) | RAB9AKDM4EMAPTNR1H2NR1H3 | |
| SCHEMBL735140 | 0.85 | KMT2A (0.41) | MAPTL3MBTL1POLBCETPLMNA | |
| SCHEMBL734806 | 0.83 | CETP (0.37) | RAB9AKDM4EMAPTL3MBTL1POLB | |
| SCHEMBL13603906 | 0.78 | RAB9A (0.48) | RAB9AKDM4EMAPTL3MBTL1POLB | |
| SCHEMBL9832874 | 0.77 | CETP (0.47) | RAB9AKDM4EMAPTCETPLMNA | |
| SCHEMBL16333174 | 0.76 | RAB9A (0.42) | RAB9AKDM4EMAPTCETPNR1H2 | |
| SCHEMBL16333309 | 0.74 | RAB9A (0.40) | RAB9AKDM4EMAPTCYP3A4 | |
| SCHEMBL1555656 | 0.74 | KMT2A (0.38) | MAPTCETPLMNATSHRSMN1; SMN2 | |
| SCHEMBL18130569 | 0.73 | L3MBTL1 (0.49) | RAB9AMAPTL3MBTL1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138175-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | RAB9A 762/4885KDM4E 3886/4885MAPT 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.